

ÇOCUK HEMATOLOJİSİ VE ONKOLOJİSİ ACİLLER

Ömer KARTAL

© Copyright 2019

Bu kitabın, basım, yayın ve satış hakları Akademisyen Kitabevi A.Ş.'ne aittir. Anılan kuruluşun izni alınmadan kitabın tümü ya da bölümleri mekanik, elektronik, fotokopi, manyetik kağıt ve/veya başka yöntemlerle çoğaltılamaz, basılamaz, dağıtılamaz. Tablo, şekil ve grafikler izin alınmadan, ticari amaçlı kullanılamaz. Bu kitap T.C. Kültür Bakanlığı bandrolü ile satılmaktadır.

ISBN

978-605-258-727-0

Kitap Adı

Çocuk Hematolojisi ve Onkolojisi Aciller

Yazar

Ömer Kartal

Yayın Koordinatörü

Yasin Dilmen

Sayfa ve Kapak Tasarımı

Akademisyen Dizgi Ünitesi

Yayıncı Sertifika No

25465

Baskı ve Cilt

Bizim Dijital Matbaa

Bisac Code

MED038000

DOI

10.37609/akya.1185

GENEL DAĞITIM

Akademisyen Kitabevi A.Ş.

Halk Sokak 5 / A

Yenişehir / Ankara

Tel: 0312 431 16 33

siparis@akademisyen.com

www.akademisyen.com

*Bu eser, ömrü boyunca kendi gibi olmayı bir yaşam tarzı haline
getirmiş, her şart ve koşulda bana destek olmuş
rahmetli annemin aziz hatırasına;*

*Hayatın ve akademik yaşamın zorlu yollarında her zaman yanımda
olmuş hayat arkadaşım kıymetli eşim Ayşe Tuğba'ya;*

*Küçük kalbiyle ailemize katıldığı ilk günden bu yana aile olmanın
kıymetini hissettiren sevgili oğlumuz İlbey Kerem' e;*

ve

*Meslek hayatımda bilgi ve tecrübeleriyle bana yol göstermiş
tüm saygı değer hocalarıma*

ithaf olunur...

İÇİNDEKİLER

I. Kardiyovasküler Aciller

Kanserle İlişkili Venöz Tromboembolizm.....	3
Santral Venöz Kateterle İlişkili Komplikasyonlar.....	9
Vena Kava Superior Sendromu.....	17
Kemoterapi Ekstravazasyonu.....	23

II. İmmün-Hematolojik Aciller

Febril Nötropeni	31
Septik Şok.....	37
Hiperlökositozis.....	43
Dissemine İntravasküler Koagülasyon	49
Kanama Diyatezi.....	55

III. Nörolojik Aciller

Spinal Kord Kompresyonu	63
Kafa İçi Basınç Artışı Sendromu	67

IV. Metabolik Aciller

Tümör Lizis Sendromu	75
Hiponatremi ve Uygunsuz ADH Sendromu	81

V. Gastrointestinal Aciller

Bulantı ve Kusma.....	89
Diare.....	97
Mukozit.....	105
Tifilitis (Nötropenik Enterokolit).....	111

VI. Kansere Bağlı Ağrı

Kansere Bağlı Ağrı Yönetimi.....	119
----------------------------------	-----

ÖNSÖZ

Tıbbın diğer dallarında olduğu gibi çocuk hematolojisi ve onkolojisi konusundaki bütün bilgiler uluslararası online veritabanları, tıp dergileri, bilimsel toplantılar ve ders kitaplarında bulunabilir. Buna karşılık acil durumlarda uygulanacak bilgilerin birçoğu bu kaynaklarda bir arada yer almamaktadır. Elinizdeki bu kitap bu eksikliği gidermek amacıyla hazırlanmıştır.

Bu kitap ne bir ders kitabı ne de bir hematoloji ve onkoloji ansiklopedisidir. Bilimsel gelişmelerin ışığında zamanla bu kitaptaki bilgilerin yeni basımlarla güncellenmesi gerekecektir.

Amacı gereği çocuk hematoloji ve onkoloji acillerinin hepsini bu kitapta bulunması beklenmemelidir. Kitap sık karşılaşılan çocuk hematoloji ve onkoloji acil konularını içermektedir.

Kitabı kendini çocuk hastaların tedavisine ve bakımına adanmış tüm hekimlerin gereksinimlerini karşılayacağını umarak değerlendirmelerinize sunuyorum.

Dr. Ömer Kartal

Kaynaklar

- Piovesan D, Attard C, Monagle P, et al. Epidemiology of venous thrombosis in children with cancer. *Thromb Haemost.* 2014;111(6):1015-1021.
- Mahajerin A, Croteau SE. Epidemiology and Risk Assessment of Pediatric Venous Thromboembolism. *Front Pediatr.* 2017;5:68.
- Heit JA. Epidemiology of venous thromboembolism. *Nat Rev Cardiol.* 2015;12(8):464-474.
- Branchford BR, Betensky M, Goldenberg NA. Pediatric issues in thrombosis and hemostasis: The how and why of venous thromboembolism risk stratification in hospitalized children. *Thromb Res.* 2018;172:190-193.
- Radulescu VC, D'Orazio JA. Venous Thromboembolic Disease in Children and Adolescents. *Adv Exp Med Biol.* 2017;906:149-165.
- Revel-Vilk S, Kenet G. Thrombophilia in children with venous thromboembolic disease. *Thromb Res.* 2006;118(1):59-65.
- Wiernikowski JT, Athale UH. Thromboembolic complications in children with cancer. *Thromb Res.* 2006;118(1):137-152.
- Horowitz N, Brenner B. Thrombophilia and cancer. *Pathophysiol Haemost Thromb.* 2008;36(3-4):131-136.
- Ko RH, Thornburg CD. Venous Thromboembolism in Children with Cancer and Blood Disorders. *Front Pediatr.* 2017;5:12.
- Athale, U., Chan, A. (2012). Thromboembolism in Children with Cancer. Scheinmann, K., Boyce A.E. (Eds.), *Emergencies in Pediatric Oncology* (pp.71-82). Springer: London.
- Chiramel, J., Salih, Z., Califano, R. (2016). Venous Thromboembolism in Cancer Patients. Pulla, M.P. (Ed.), *Esmo Handbook of Oncological Emergencies* (pp.17-29). ESMO Press: Switzerland.
- O'Brien SH. Recognition and management of pediatric venous thromboembolism in the emergency department. *Clin Pediatr Emerg Med.* 2011;12:185-190.
- Rühle F, Stoll M. Advances in predicting venous thromboembolism risk in children. *Br J Haematol.* 2018;180(5):654-665.
- Lyle CA, Sidonio RF, Goldenberg NA. New developments in pediatric venous thromboembolism and anticoagulation, including the target-specific oral anticoagulants. *Curr Opin Pediatr.* 2015;27(1):18-25.

Kaynaklar

- Duesing LA, Fawley JA, Wagner AJ. Central Venous Access in the Pediatric Population With Emphasis on Complications and Prevention Strategies. *Nutr Clin Pract*. 2016;31(4):490-501.
- Jamshidi R. Central venous catheters: Indications, techniques, and complications. *Semin Pediatr Surg*. 2019;28(1):26-32.
- Askegard-Giesmann JR, Caniano DA, Kenney BD. Rare but serious complications of central line insertion. *Semin Pediatr Surg*. 2009;18(2):73-83.
- Simon EM, Summers SM. Vascular Access Complications: An Emergency Medicine Approach. *Emerg Med Clin North Am*. 2017;35(4):771-788.
- Ares G, Hunter CJ. Central venous access in children: indications, devices, and risks. *Curr Opin Pediatr*. 2017;29(3):340-346.
- Albanese CT, wiener ES. Venous Access in Pediatric Oncology Patients. *Seminars in Surgical Oncology*. 1993;9:467-477.
- Güleser GN, Taşçı S. Onkolojide Sık Kullanılan Santral Venöz Kateterleri ve Bakımı. *F.Ü. Sağ.Bil.Tıp Derg*. 2009;23 (1): 47-51.
- Volkov, N., Moiseenko, F. (2016). Complications of Central Venous Devices. Pulla, MP. (Ed.), *Esmo Handbook of Oncological Emergencies* (pp.39-48). ESMO Press: Switzerland.
- Moir D, Bodenham A. A narrative review of long-term central venous access devices for the intensivist. *J Intensive Care Soc*. 2018;19(3):236-246.
- Ullman AJ, Marsh N, Mihala G, et al. Complications of Central Venous Access Devices: A Systematic Review. *Pediatrics*. 2015;136(5):e1331-44.
- Toro, A., Biffi, R., Di Carlo, I. (2014). Catheter-related Bloodstream Infection. Di Carlo, I., Biffi, R. (Eds.), *Totally Implantable Venous Access Devices* (PP.167-172). Springer: Italy.
- O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. *Clin Infect Dis*. 2011;52(9):e162-193.
- Wigmore TJ, Smythe JF, Hacking MB, et al. Effect of the implementation of NICE guidelines for ultrasound guidance on the complication rates associated with central venous catheter placement in patients presenting for routine surgery in a tertiary referral centre. *Br J Anaesth*. 2007;99(5):662-665.
- Janum S, Zingg W, Classen V, et al. Bench-to-bedside review: challenges of diagnosis, care and prevention of central catheter-related bloodstream infections in children. *Crit Care*. 2013;17(4):238.
- Athale, U., Chan, A. (2012). Central Venous Line-related Thrombosis. Scheinemann, K., Boyce, AE. (Eds.), *Emergencies in Pediatric Oncology* (pp.91-104). Springer: Canada.
- Marschall J, Mermel LA, Fakih M, et al. Strategies to prevent central line-associated bloodstream infections in acute care hospitals: 2014 update. *Infect Control Hosp Epidemiol*. 2014;35:S89-107.
- Vidal E, Sharathkumar A, Glover J, et al. Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis: reply. *J Thromb Haemost*. 2015;13(1):161-162.
- Debourdeau P, Farge D, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. *J Thromb Haemost*. 2013;11(1):71-80.

- Baskin J, Pui C, Reiss U, et al. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. *Lancet*. 2009;374(9684):159–169.
- Wiegering V, Schmid S, Andres O, et al. Thrombosis as a complication of central venous access in pediatric patients with malignancies: a 5-year singlecenter experience. *BMC Hematol*. 2014; 14:18.

Kaynaklar

- Nossair F, Schoettler P, Starr J, et al. Pediatric superior vena cava syndrome: An evidence-based systematic review of the literature. *Pediatr Blood Cancer*. 2018;65(9):e27225.
- Prusakowski MK, Cannone D. Pediatric Oncologic Emergencies. *Hematol Oncol Clin North Am*. 2017;31(6):959-980.
- Henry M, Sung L. Supportive care in pediatric oncology: oncologic emergencies and management of fever and neutropenia. *Pediatr Clin North Am*. 2015;62(1):27-46.
- Freedman, JL., Rheingold, SR. (2016). Management of oncologic emergencies. Lanzkowsky, P., Lipton, JM., Fish, JD. (Eds), *Lanzkowsky's manual of pediatric hematology and oncology* (6th, pp. 610-611). USA: Academic press.
- McCurdy MT, Shanholtz CB. Oncologic emergencies. *Crit Care Med*. 2012;40(7):2212-22.
- Straka C, Ying J, Kong FM, et al. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome. *Springerplus*. 2016;5:229.
- Wan JF, Bezjak A. Superior vena cava syndrome. *Emerg Med Clin North Am*. 2009;27(2):243-255.
- Seth R, Bhat AS. Management of common oncologic emergencies. *Indian J Pediatr*. 2011;78(6):709-717.
- Eyman, RS., Cesur, EE. (2015). Vena kava superior sendromu. BALCI, AE. (Ed), *Mediyasten hastalıkları ve cerrahisi* (s. 185-195). Türkiye: TÜSAD.
- Gupta V, Ambati SR, Pant P, et al. Superior vena cava syndrome in children. *Indian J Hematol Blood Transfus*. 2008;24(1):28-30.
- Tzifa A, Marshall AC, McElhinney DB, et al. Endovascular treatment for superior vena cava occlusion or obstruction in a pediatric and young adult population: a 22-year experience. *J Am Coll Cardiol*. 2007;49:1003-1009.
- Stricker PA, Gurnaney HG, Litman RS. Anesthetic management of children with an anterior mediastinal mass. *J Clin Anesth*. 2010;22(3):159-163.
- Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. *N Engl J Med*. 2007;356(18):1862-1869.
- Tilak TV, Raina V, Kumar L, et al. Superior vena cava syndrome and poor performance status at presentation affect survival in mediastinal T-lymphoblastic lymphoma—a single institute experience from India. *Ann Hematol*. 2013;92:917-923.

Kaynaklar

- Boschi R, Rostagno E. Extravasation of antineoplastic agents: prevention and treatments. *Pediatr Rep.* 2012;4(3):e28.
- Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. *Ann Oncol.* 2012;7:167-173.
- Goolsby TV, Lombardo FA. Extravasation of chemotherapeutic agents: prevention and treatment. *Semin Oncol.* 2006;33(1):139-143.
- Doğru, Ö. (2009). Ekstravazasyon. Özkan, A. (Ed.), *Pediyatrik onkoloji* (s. 1301-1305). Türkiye:Nobel.
- Langer SW. Extravasation of chemotherapy. *Curr Oncol Rep.* 2010;12(4):242-246.
- Boulanger J, Ducharme A, Dufour A. Management of the extravasation of anti-neoplastic agents. *Support Care Cancer.* 2015;23(5):1459-1471.
- Kreidieh FY, Moukadem HA, El Saghir NS. Overview, prevention and management of chemotherapy extravasation. *World J Clin Oncol.* 2016;7(1):87-97.
- Unsel, M., Thallinger, C. (2016). Extravasation of Chemotherapy. Pulla, MP. (Ed.), *Esmo Handbook of Oncological Emergencies* (pp.58-68). ESMO Press: Switzerland.
- Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. *Ann Oncol.* 2004;15:858-862.
- Wengstrom Y, Margulies A. European Oncology Nursing Society extravasation guidelines. *European Journal of Oncology Nursing* 2008;12:357-61.
- Sauerland C, Engelking C, Wickham R, et al. Vesicant extravasation part I: mechanisms, pathogenesis, and nursing care to reduce risk. *Oncology Nursing Forum.* 2006;33:1134-1141.

Kaynaklar

- Barton CD, Waugh LK, Nielsen MJ, et al. Febrile neutropenia in children treated for malignancy. *J Infect.* 2015;71:27-35.
- Kebudi R, Kizilocak H. Febrile Neutropenia in Children with Cancer: Approach to Diagnosis and Treatment. *Curr Pediatr Rev.* 2018;14(3):204-209.
- Meckler G, Lindemulder S. Fever and neutropenia in pediatric patients with cancer. *Emerg Med Clin North Am.* 2009;27(3):525-544.
- Kebudi, R. (2009). Ateşli nötropenik çocuklarda Türkiyede durum. Özkan, A. (Ed.), *Pediatric onkoloji* (s. 1263-1266). Türkiye:Nobel.
- Crokaert F. Febrile neutropenia in children. *Int J Antimicrob Agents.* 2000;16(2):173-176.
- Bakhshi S, Padmanjali KS, Arya LS. Infections in childhood acute lymphoblastic leukemia: an analysis of 222 febrile neutropenic episodes. *Pediatr Hematol Oncol.* 2008;25(5):385-392.
- Ören, H., Karakaş, Z., Güneş, AM. (2016). *Pediatric febril nötropeni*. İstanbul:Galenos yayınevi.
- Viscoli C, Castagnola E. Treatment of febrile neutropenia: what is new? *Curr Opin Infect Dis.* 2002;15(4):377-382.
- Orudjev E, Lange BJ. Evolving concepts of management of febrile neutropenia in children with cancer. *Med Pediatr Oncol.* 2002;39(2):77-85.
- Freifeld AG, Bow EJ, Kent A, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. *Clin Infect Dis.* 2011; 52(4): 56-93.
- Celkan, T. *Pediatric kanser hastalarında ateşli nötropeni*. *Klinik gelişim.* 2007;20(2):182-195.
- Alexander SW, Wade KC, Hibberd PL, et al. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. *J Pediatr Hematol Oncol.* 2002; 24(1): 38-42.
- Rondinelli PI, Ribeiro KdeC, de Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. *J Pediatr Hematol Oncol.* 2006; 28(10): 665-70.
- Han SB, Bae EY, Lee JW, et al. Clinical characteristics and antibiotic susceptibility of viridans streptococcal bacteraemia in children with febrile neutropenia. *Infection Oct.* 2013;41(5):917e24.

Kaynaklar

- Silverman AM. Septic shock: recognizing and managing this life-threatening condition in pediatric patients. *Pediatr Emerg Med Pract.* 2015;12(4):1-25.
- Maloney PJ. Sepsis and septic shock. *Emerg Med Clin North Am.* 2013;31(3):583-600.
- Skippen P, Kissoon N, Waller D, et al. Sepsis and septic shock: progress and future considerations. *Indian J Pediatr.* 2008;75(6):599-607.
- Khilnani P, Deopujari S, Carcillo J. Recent advances in sepsis and septic shock. *Indian J Pediatr.* 2008;75(8):821-830.
- Martin K, Weiss SL. Initial resuscitation and management of pediatric septic shock. *Minerva Pediatr.* 2015;67(2):141-158.
- Kutko MC, Calarco MP, Flaherty MB, et al. Mortality rates in pediatric septic shock with and without multiple organ system failure. *Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.* 2003; 4:333-337.
- Çıtak A. Çocukluk Yaş Grubunda Şok ve Tedavisi. *Çocuk Dergisi.* 2012;12(3):99-112.
- Balamuth F, Weiss SL, Neuman MI, et al. Pediatric severe sepsis in U.S. children's hospitals. *Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.* 2014; 15:798-805.
- Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. *Critical care medicine.* 2013;41: 580-637.
- Yıldıztaş D., Demirkol D. Türkiye Milli Pediatri Derneği Çocuk Acil Tıp ve Yoğun Bakım Derneği Ortak Tanı ve Tedavi Kılavuzu.2014;27-38.
- Han YY, Carcillo JA, Dragotta MA, et al. Early reversal of pediatric-neonatal septic shock by community physicians is associated with improved outcome. *Pediatrics.* 2003; 112:793-799.
- Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. *Critical care medicine.* 2009; 37:666-688.

Kaynaklar

- Giammarco S, Chiusolo P, Piccirillo N, et al. Hyperleukocytosis and leukostasis: management of a medical emergency. *Expert Rev Hematol.* 2017;10(2):147-154.
- Ruggiero A, Rizzo D, Amato M, et al. Management of Hyperleukocytosis. *Curr Treat Options Oncol.* 2016;17(2):7.
- Piro E, Carillio G, Levato L, et al. Reversal of leukostasis-related pulmonary distress syndrome after leukapheresis and low-dose chemotherapy in acute myeloid leukemia. *J Clin Oncol.* 2011;29(26):e725-726.
- Stucki A, Rivier AS, Gikic M, et al. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. *Blood.* 2001;97(7):2121-2129.
- Korkmaz S. The management of hyperleukocytosis in 2017: Do we still need leukapheresis? *Transfus Apher Sci.* 2018;57(1):4-7.
- Ganzel C, Becker J, Mintz PD, et al. Hyperleukocytosis, leukostasis and leukapheresis: practice management. *Blood Rev.* 2012;26:117-122.
- Kuku İ, Kaya E, Erkurt MA, et al. Hiperlökositozlu Lösemi Hastalarımızda Terapötik ve Profilaktik Lökoferez Deneyimlerimiz. *İnönü Üniversitesi Tıp Fakültesi Dergisi.* 2004;11(4):243-246.
- Daver N, Kantarjian H, Marcucci G, et al. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. *J Haematol.* 2015;168:646-653.
- Porcu P, Farag S, Marcucci G, et al. Leukocytoreduction for acute leukemia. *Ther Apher.* 2002;6(1):15-23.
- Porcu P, Danielson CF, Orazi A, et al. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. *Br J Haematol.* 1997;98(2):433-436.
- Blum W, Porcu P. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. *Semin Thromb Hemost.* 2007;33(4):350-354.

Kaynaklar

- Rajagopal R, Thachil J, Monagle P. Disseminated intravascular coagulation in paediatrics. *Arch Dis Child*. 2017;102(2):187-193.
- Wada H, Matsumoto T, Yamashita Y, et al. Disseminated intravascular coagulation: testing and diagnosis. *Clin Chim Acta*. 2014;436:130-134.
- Saba HI, Morelli GA, Saba RI. Disseminated Intravascular Coagulation (DIC) in cancer. *Cancer Treat Res*. 2009;148:137-156.
- Büyükaşık Y. Dissemine intravasküler koagülasyon. *Yoğun Bakım Dergisi*. 2004;4(1):5-12.
- Levi M. Disseminated intravascular coagulation in cancer patients. *Best Pract Res Clin Haematol*. 2009;22(1):129-136.
- Saynak M, Yürüt-çaloğlu V, Bayır G, et al. Kanser hastalarında düşük molekül ağırlıklı heparin'in sağkalım üzerine etkisi. *Türk Onkoloji Dergisi*. 2006;21(1):42-46.
- Franchini M, Di Minno MN, Coppola A. Disseminated intravascular coagulation in hematologic malignancies. *Semin Thromb Hemost*. 2010;36(4):388-403.
- Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. *J Intensive Care*. 2014;2(1):15.
- Gezer S. Dissemine intravasküler koagülasyonun tanı ve tedavisi. *Türk hematoloji derneği*. 2012;2:97-111.
- Di Nisio M, Baudo F, Cosmi B, et al. Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). *Thromb Res*. 2012;129(5):e177-184.
- Soundar EP, Jariwala P, Nguyen TC, et al. Evaluation of the International Society on Thrombosis and Haemostasis and institutional diagnostic criteria of disseminated intravascular coagulation in pediatric patients. *Am J Clin Pathol*. 2013;139:812-816.
- Sola-Visner M. Platelets in the neonatal period: developmental differences in platelet production, function, and hemostasis and the potential impact of therapies. *Hematology Am Soc Hematol Educ Program*. 2012;2012:506-511.
- Jhang WK, Ha EJ, Park SJ. Evaluation of disseminated intravascular coagulation scores in critically ill pediatric patients. *Pediatr Crit Care Med*. 2016;17:e239-246.

Kaynaklar

- Graham RA, Davis JA, Corrales-Medina FF. The Adolescent with Menorrhagia: Diagnostic Approach to a Suspected Bleeding Disorder. *Pediatr Rev.* 2018;39(12):588-600.
- Key NS. Diagnostic approaches to bleeding disorders. *Hematology.* 2005;10:29-32.
- Bansal D, Oberoi S, Marwaha RK, Singhi SC. Approach to a child with bleeding in the emergency room. *Indian J Pediatr.* 2013;80(5):411-420.
- Allen GA, Glader B. Approach to the bleeding child. *Pediatr Clin North Am.* 2002;49(6):1239-1256.
- Revel-Vilk, S., Rand ML., Israels SJ. (2013). An Approach to the Bleeding Child. Blanchette, VS., Breakey, VR., Revel-Vilk, S. (Eds), *SickKids Handbook of Pediatric Thrombosis and Hemostasis* (pp. 14–22). Karger: Basel.
- Celkan T. Kanama diyatez testlerinin yorumlanması. *Türk çocuk hematoloji dergisi.* 2006;2:18-27.
- Revel-Vilk S. Clinical and laboratory assessment of the bleeding pediatric patient. *Semin Thromb Hemost.* 2011;37(7):756-762.
- Salles II, Feys HB, Iserbyt BF, et al. Inherited traits affecting platelet function. *Blood Rev.* 2008;22(3):155–172.
- Gezer S. Kanama diyatezi olan hastaya yaklaşım. *HematoLog.* 2012; 2:1-7.
- Bowman M, Hopman WM, Rapson D, et al. The prevalence of symptomatic von Willebrand disease in primary care practice. *J Thromb Haemost.* 2010;8(1):213–216.
- Yenicesu İ. Kanama diyatezi olan hastaya yaklaşım. *Sted.* 2002;11:6-7.
- Rajpurkar, M., Lusher, JM. (2009). *Clinical and Laboratory Approach to the Patient with Bleeding.* Orkin, SH., Fisher, DE., Look, AT., Lux, SE., Ginsburg, D., Nathan, DG. (Eds), *Nathan and Oski's Hematology of Infancy and Childhood* (7th ed), (1449-1461). Saunders Elsevier:Philadelphia.
- Levi M, Meijers JC. DIC: which laboratory tests are most useful. *Blood Rev.* 2011;25:33–37.

Kaynaklar

- Pollono D, Tomarchia S, Drut R, et al. Spinal cord compression: a review of 70 pediatric patients. *Pediatr Hematol Oncol*. 2003;20(6):457-466.
- Joaquim AF, Ghizoni E, Valadares MGC, et al. Spinal tumors in children. *Rev Assoc Med Bras*. 2017;63(5):459-465.
- Wilne S, Walker D. Spine and spinal cord tumours in children: a diagnostic and therapeutic challenge to healthcare systems. *Arch Dis Child Educ Pract Ed*. 2010;95(2):47-54.
- Pi J, Kang Y, Smith M, et al. A review in the treatment of oncologic emergencies. *J Oncol Pharm Pract*. 2016;22(4):625-638.
- Patel DA, Campian JL. Diagnostic and Therapeutic Strategies for Patients with Malignant Epidural Spinal Cord Compression. *Curr Treat Options Oncol*. 2017;18(9):53.
- Brooks FM, Ghatahora A, Brooks MC, et al. Management of metastatic spinal cord compression: awareness of NICE guidance. *Eur J Orthop Surg Traumatol*. 2014;24:255-259.
- Al-Qurainy R, Collis E. Metastatic spinal cord compression: diagnosis and management. *BMJ*. 2016;353:i2539.
- Boussios S, Cooke D, Hayward C, et al. Metastatic Spinal Cord Compression: Unraveling the Diagnostic and Therapeutic Challenges. *Anticancer Res*. 2018;38(9):4987-4997.
- Penas-Prado M, Loghin ME. Spinal cord compression in cancer patients: review of diagnosis and treatment. *Curr Oncol Rep*. 2008;10(1):78-85.
- Delank KS, Wendtner C, Eich HT, et al. The treatment of spinal metastases. *Dtsch Arztebl Int*. 2011;108(5):71-79.
- Çorapcıoğlu, F. (2009). Nörolojik aciller. Özkan, A. (Ed.), *Pediyatrik onkoloji* (s. 1235-1241). Türkiye:Nobel.
- Fenoy AJ, Greenlee JD, Menezes AH, et al. Primary bone tumors of the spine in children. *J Neurosurg*. 2006;105(4):252-260.
- Clarke MJ, Mendel E, Vrionis FD. Primary spine tumors: diagnosis and treatment. *Cancer Control*. 2014; 21(2):114-123.

Kaynaklar

- Ramesh KR, Singhi SC, Singhi P. Raised intracranial pressure (ICP): management in emergency department. *Indian J Pediatr.* 2012;79(4):518-524.
- Sankhyan N, Vykunta Raju KN, Sharma S, et al. Management of raised intracranial pressure. *Indian J Pediatr.* 2010;77(12):1409-1416.
- Pitfield AF, Carroll AB, Kissoon N. Emergency management of increased intracranial pressure. *Pediatr Emerg Care.* 2012;28(2):200-204.
- Palmer J. Management of raised intracranial pressure in children. *Intensive Crit Care Nurs.* 2000;16(5):319-327.
- Emmez ÖH, Egemen E. Practical Management of Intracranial Hypertension. *Yoğun Bakım Dergisi* 2010;9(2):77-84.
- Aylward SC, Way AL. Pediatric Intracranial Hypertension: a Current Literature Review. *Curr Pain Headache Rep.* 2018;22(2):14-23.
- Castillo LR, Gopinath S, Robertson CS. Management of intracranial hypertension. *Neurol Clin.* 2008;26:521-541.
- Marcoux KK. Management of increased intracranial pressure in critically ill child with acute neurological injury. *AACN Clin Issues.* 2005;16:212-231.
- Karaaslan B, Börcek AÖ. Pediatrik beyin tümörlerinde cerrahi yaklaşım. *Türkiye Klinikleri J Radiat Oncol-Special Topics.* 2016;2(2):1-9.
- Rabinstein AA. Treatment of cerebral edema. *Neurologist.* 2006;12:59-73.
- Adelson PA, Bratton SL, Carney NA, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children and adolescents. *Pediatr Crit Care Med.* 2003;4:72-75.
- Gwer S, Gatakaa H, Mwai L, et al. The role for osmotic agents in children with acute encephalopathies: a systematic review. *BMC Pediatr.* 2010;10:23-31.
- Inger HE, Rogers DL, McGregor ML, et al. Diagnostic criteria in pediatric intracranial hypertension. *J AAPOS: the official publication of the American Association for Pediatric Ophthalmology and Strabismus / American Association for Pediatric Ophthalmology and Strabismus.* 2017;21(6):492-495.

Kaynaklar

- Celkan T, Tüysüz G. Tumour lysis syndrome; new approaches at diagnose, follow up and treatment. *Türk Ped Arş.* 2013;48:188-194.
- Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. *J Clin Oncol.* 2008;26(16):2767-2778.
- Zonfrillo MR. Management of pediatric tumor lysis syndrome in the emergency department. *Emerg Med Clin North Am.* 2009;27(3):497-504.
- Strauss PZ, Hamlin SK, Dang J. Tumor Lysis Syndrome: A Unique Solute Disturbance. *Nurs Clin North Am.* 2017;52(2):309-320.
- Stephanos K, Picard L. Pediatric Oncologic Emergencies. *Emerg Med Clin North Am.* 2018;36(3):527-535.
- Freedman, JL., Rheingold, SR. (2016). Management of oncologic emergencies. Lanzkowsky, P., Lipton, JM., Fish, JD. (Eds), *Lanzkowsky's manual of pediatric hematology and oncology* (6th, pp. 605-610). USA: Academic press.
- Pession A, Masetti R, Gaidano G, et al. Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: consensus of an Italian expert panel. *Adv Ther.* 2011;28(8):684-697.
- Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. *Brit J Haematol.* 2004;127(1):3-11.
- Hochberg J, Cairo MS. Tumor lysis syndrome: current perspective. *Haematologica.* 2008;93(1):9-13.
- Locatelli F, Rossi F. Incidence and pathogenesis of tumor lysis syndrome. *Contrib Nephrol.* 2005;147:61-68.
- Kobayashi D, Wofford MM, McLean TW, et al. Spontaneous tumor lysis syndrome in a child with T-cell acute lymphoblastic leukemia. *Pediatr Blood Cancer.* 2010;54(5):773-775.
- Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. *Blood.* 2001;97(10):2998-3003.
- Annemans L, Moeremans K, Lamotte M, et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. *Leuk Lymphoma.* 2003;44(1):77-83.
- Montesinos P, Lorenzo I, Martin G, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. *Haematologica.* 2008;93(1):67-74.
- Wossmann W, Schrappe M, Meyer U, et al. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. *Ann Hematol.* 2003;82(3):160-165.
- Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. *Leukemia.* 2005;19(1):34-38.
- Andreoli SP, Clark JH, McGuire WA, et al. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. *J Pediatr.* 1986;109(2):292-298.

- Feusner JH, Ritchey AK, Cohn SL, et al. Management of tumor lysis syndrome: need for evidence-based guidelines. *J Clin Oncol.* 2008;26(34):5657–5658.
- Cheah CY, Lew TE, Seymour JF, et al. Rasburicase causing severe oxidative hemolysis and methemoglobinemia in a patient with previously unrecognized glucose-6-phosphate dehydrogenase deficiency. *Acta Haematol.* 2013;130(4):254–259.

Kaynaklar

- Raftopoulos H. Diagnosis and management of hyponatremia in cancer patients. *Support Care Cancer*. 2007;15(12):1341-1347.
- Berardi R, Rinaldi S, Caramanti M, et al. Hyponatremia in cancer patients: Time for a new approach. *Crit Rev Oncol Hematol*. 2016;102:15-25.
- Jones DP. Syndrome of Inappropriate Secretion of Antidiuretic Hormone and Hyponatremia. *Pediatr Rev*. 2018;39(1):27-35.
- Çipil H, Demircioğlu S. Hiponatremi and syndrome of inappropriate ADH. *Turkiye Klinikleri J Hematol-Special Topics*. 2016;9(3):16-20.
- Doshi SM, Shah P, Lei X, et al. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. *Am J Kidney Dis*. 2012;59(2):222-228.
- Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. *Support Care Cancer*. 2000;8(3):192-127.
- Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. *N Engl J Med*. 2007;356(20):2064-2072.
- Haycock GB. The syndrome of inappropriate secretion of antidiuretic hormone. *Pediatr Nephrol* 1991;9:375-381.
- Akman S, Güven AG. Hyponatremia: Clinical evaluation and treatment. *Official Journal of the Turkish Society of Nephrology*. 2001;10(2):68-72.
- Adler SM, Verbalis JG. Disorders of body water homeostasis in critical illness. *Endocrinol Metab Clin North Am*. 2006;35:873-894.
- Robertson GL. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. *Am J Med*. 2006;119:36-42.
- Feldman BJ, Rosenthal SM, Vargas GA, et al. Nephrogenic syndrome of inappropriate antidiuresis. *N Engl J Med*. 2005;352(18):1884-1890.
- Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. *Nephrol Dial Transplant* 2014;29:1-39.
- Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. *Am J Med*. 2007;120(11):1-21.
- Sorensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. *J Intern Med*. 1995;238(2):97-110.

Kaynaklar

- Dewan P, Singhal S, Harit D. Management of chemotherapy-induced nausea and vomiting. *Indian Pediatr.* 2010;47(2):149-155.
- Antonarakis ES, Hain RD. Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice. *Arch Dis Child.* 2004;89(9):877-880.
- Dupuis LL, Robinson PD, Boodhan S, et al. Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients. *Pediatr Blood Cancer.* 2014;61(8):1506-1512.
- Patel P, Robinson PD, Thackray J, et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update. *Pediatr Blood Cancer.* 2017;64(10):1-12.
- Flank J, Robinson PD, Holdsworth M, et al. Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer. *Pediatr Blood Cancer.* 2016;63(7):1144-1151.
- Dupuis LL, Boodhan S, Sung L, et al. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. *Pediatr Blood Cancer.* 2011;57(2):191-198.
- Mountzios, G., Petrova, M. (2016). Nausea and Vomiting. Pulla, M.P. (Ed.), *Esmo Handbook of Oncological Emergencies* (pp.157-163). ESMO Press: Switzerland.
- Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present and future recommendations. *Oncologist.* 2007;12: 1143-1150.
- American Society of Clinical Oncology, Kris MG, Hesketh PJ, et al. American Society of Clinical Oncology guideline for antiemetics in oncology:Update 2006. *J Clin Oncol.* 2006;24:2932-2947.
- Aşçı H, Özer MK. Treatment Proposals for Nausea and Vomiting. *S.D.Ü. Sağlık Bilimleri Enstitüsü Dergisi.* 2011;3(2);160-165.
- Gralla RJ, de Wit R, Herrstedt J, et al. Anti-emetic efficacy of the neurokinin-1 antagonist, aprepitant, plus 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high dose cisplatin: analysis of combined data from two phase III randomized controlled clinical trials. *Cancer.* 2005;15;864-868.
- Hesketh PJ, Grunberg SM, Herrstedt J, et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. *Support Care Cancer.* 2006;14:354-360.
- Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. *Ann Oncol.* 2006;17:1000-1006.
- Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. *Cancer.*2008;112: 2080-2087.
- Grunberg SM, Dugan M, Muss H, et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. *Support Care Cancer* 2009; 17: 589-594.

- Grote T, Hajdenberg J, Cartmell A, et al. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. *J Support Oncol.* 2006;4:403-408.
- Gore L, Chawla S, Petrilli A, et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled study of efficacy and tolerability. *Pediatr Blood Cancer.* 2009;52:242-247.
- White L, Daly SA, McKenna CJ, et al. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy. *Pediatr Hematol Oncol.* 2000;17:445-455.

Kaynaklar

- Gibson RJ, Keefe DM. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. *Support Care Cancer*. 2006;14(9):890-900.
- Richardson G, Dobish R. Chemotherapy induced diarrhea. *J Oncol Pharm Pract*. 2007;13(4):181-198.
- Andreyev J, Ross P, Donnellan C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. *Lancet Oncol*. 2014;15(10):447-460.
- Escalante J, McQuade RM, Stojanovska V, et al. Impact of chemotherapy on gastrointestinal functions and the enteric nervous system. *Maturitas*. 2017;105:23-29.
- Pérez-Callejo, D., Calvo, V. (2016). Diarrhoea. Pulla, M.P. (Ed.), *Esmo Handbook of Oncological Emergencies* (pp.172-182). ESMO Press: Switzerland.
- Kornblau S, Benson AB, Catalano R, et al. Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. *J Pain Symptom Manage*. 2000;19(2):118-129.
- Tseitlin, H. (2012). Abdominal Complications. Scheinmann, K., Boyce A.E. (Eds.), *Emergencies in Pediatric Oncology* (pp.143-154). Springer: London.
- Arbuckle RB, Huber SL, Zacker C. The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. *Oncologist*. 2000; 5: 250–259.
- Borner MM, Bernhard J, Dietrich D, et al. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality of life and toxicity. *Ann Oncol*. 2005; 16: 282–288.
- Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Effects, Version 3.0. National Cancer Institute, Bethesda; National Institutes of Health, U.S. Department of Health and Human Services. December 12, 2003.
- Saliba F, Hagipantelli R, Missel JL, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. *J Clin Oncol*. 1998; 16: 2745–2751.
- Öztürk R. Akut Diyare. *Gastrointestinal sistem hastalıkları sempozyumu*. 2001;27-56.
- Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. *J Clin Oncol*. 1997; 15: 251–260.
- Jansman FGA, Sleijfer DT, de Graaf JC, et al. Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. *Drug Saf* 2001; 24: 353–367.
- Arnold RJG, Gabrail N, Raut M, et al. Clinical implications of chemotherapy-induced diarrhea. *J Support Oncol*. 2005; 3: 227–232.

Kaynaklar

- Bowen JM, Wardill HR. Advances in the understanding and management of mucositis during stem cell transplantation. *Curr Opin Support Palliat Care*. 2017;11(4):341-346.
- Villa A, Sonis ST. Mucositis: pathobiology and management. *Curr Opin Oncol*. 2015;27(3):159-164.
- Kuiken NS, Rings EH, Tissing WJ. Risk analysis, diagnosis and management of gastrointestinal mucositis in pediatric cancer patients. *Crit Rev Oncol Hematol*. 2015;94(1):87-97.
- Treister N, Sonis S. Mucositis: biology and management. *Curr Opin Otolaryngol Head Neck Surg*. 2007;15(2):123-129.
- Tomlinson D, Judd P, Hendershot E, et al. Measurement of oral mucositis in children: a review of the literature. *Support Care Cancer*. 2007;15(11):1251-1258.
- Celkan, T. Kanserli çocuklarda mukozit. *Klinik gelişim*. 2007;20(2):195-198.
- Harris DJ, Eilers J, Harriman A, et al. Putting evidence into practice: evidence-based interventions for the management of oral mucositis. *Clin J Oncol Nurs*. 2008;12:141-152.
- Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. *Cancer*. 2004;100:2026-2046.
- Potting CM, Uitterhoeve R, Op Reimer WS, et al. The effectiveness of commonly used mouthwashes for the prevention of chemotherapy-induced oral mucositis: a systematic review. *Eur J Cancer Care (Engl)*. 2006;15:431-439.
- Worthington HV, Clarkson JE, Bryan G, et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. *Cochrane Database Syst Rev*. 2011;4:CD000978.
- Dueñas-Gonzalez A, Sobrevilla-Calvo P, Frias-Mendivil M, et al. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. *Bone Marrow Transplant*. 1996;17:809-812.
- El-Housseiny AA, Saleh SM, El-Masry AA, et al. The effectiveness of vitamin "E" in the treatment of oral mucositis in children receiving chemotherapy. *J Clin Pediatr Dent*. 2007;31:167-170.
- Pytlík R, Benes P, Patorková M, et al. Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplantpatients: a randomized, double-blind, placebo controlled study. *Bone Marrow Transplant*. 2002;30:953-961.
- Lilleby K, Garcia P, Gooley T, et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant*. 2006;37:1031-1035.
- Patte C, Laplanche A, Bertozzi AI, et al. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology. *J Clin Oncol*. 2002;20:441-448.
- Waśko-Grabowska A, Rzepecki P, Oborska S, et al. Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience. *Transplant Proc*. 2011;43:3111-113.
- Horsley P, Bauer JD, Mazkowiack R, et al. Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation. *Support Care Cancer*. 2007;15:105-109.

- Aquino VM, Harvey AR, Garvin JH, et al. A double-blind randomized placebocontrolled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. *Bone Marrow Transplant.*2005;36(7):611–616.
- Stiff PJ, Erder H, Bensinger WI, et al. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). *Bone Marrow Transplant.*2006; 37(4):393–401.

Kaynaklar

- Bremer CT, Monahan BP. Necrotizing enterocolitis in neutropenia and chemotherapy: a clinical update and old lessons relearned. *Curr Gastroenterol Rep.* 2006;8(4):333-341.
- Davila ML. Neutropenic enterocolitis. *Curr Opin Gastroenterol.* 2006;22(1):44-47.
- Rodrigues FG, Dasilva G, Wexner SD. Neutropenic enterocolitis. *World J Gastroenterol.* 2017;23(1):42-47.
- Portugal R, Nucci M. Typhlitis (neutropenic enterocolitis) in patients with acute leukemia: a review. *Expert Rev Hematol.* 2017;10(2):169-174.
- Pestalozzi BC, Sotos GA, Choyke PL, et al. Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer. *Cancer.* 1993;71:1797-1800.
- Hiruki T, Fernandes B, Ramsay J, et al. Acute typhlitis in an immunocompromised host: report of an unusual case and review of the literature. *Dig Dis Sci.* 1992;37:1292-1296.
- Moore FA, Feliciano DV, Andrassy RJ, et al. Early enteral feeding, compared with parenteral, reduces postoperative septic complications: the results of a meta-analysis. *Ann Surg.* 1992;216:172-183.
- Öncü S. Neutropenic Enterocolitis. *Klimik Dergisi.* 2009; 22(3): 75-78.
- Blijlevens NMA, Donnelly JP, De Pauw BE. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview *Bone Marrow Transp.* 2000;25:1269-1278.
- Urbach DR, Rotstein OD. Typhlitis. *Can J Surg.* 1999;42(6):415-419.
- Kefe DM, Schubert MM, Elting LS, et al. Updated Clinical Practice Guidelines for the Prevention and Treatment of Mucositis. *Cancer* 2007;109:820-831.
- Avigan D, Richardson P, Elias A, et al. Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series with a review of the literature. *Cancer.* 1998; 83: 409-414.
- Wenzel C, Urbauer E, Schwarz C, et al. Severe enteropathy associated with raltitrexed and oxaliplatin chemotherapy: report of two patients experiencing this rare, potentially lethal gastrointestinal adverse event. *Anticancer Drugs.* 2006; 17:865-868.
- Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. *J Clin Oncol* 2007;25: 3158-3167.
- Gadducci A, Gargini A, Palla E, et al. Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: a case report and review of the literature. *Anticancer Res.* 2005; 25:2509–2514.
- Seewaldt, VL, Cain JM, Goff BA, et al. A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer. *Gynecol Oncol.* 1997;67:137–140.
- Vlasveld LT, Ten Bokkel HW, Rodenhuis S. Neutropenic enterocolitis in a woman with ovarian cancer after treatment with high-dose carboplatin and granulocyte macrophage-colony stimulating factor. *Neth J Med.* 1990; 37:158–161.
- Gorschluter M, Mey U, Strehl J, et al. Invasive fungal infections in neutropenic enterocolitis: A systematic review of pathogens, incidence, treatment and mortality in adult patients. *BMC Infect Dis.* 2006; 6(1):35.

Kaynaklar

- Sarihan E, Kadiolu E, İğde FA. Kanser ağrısı, tedavi prensipleri ve dünya sağlık örgütü ağrı basamak tedavisi. *Nobel Med.* 2012;8(1):5-15.
- Emir S, Cin Ş. Çocuklarda ağrı: değerlendirme ve yaklaşım. *Ankara üniversitesi tıp fakültesi mecmuası.*2004;57(3):153-160.
- Russo MM, Sundaramurthi T. An Overview of Cancer Pain: Epidemiology and Pathophysiology. *Semin Oncol Nurs.* 2019;35(3):223-228.
- Fink RM, Gallagher E. Cancer Pain Assessment and Measurement. *Semin Oncol Nurs.* 2019;35(3):229-234.
- Smith TJ, Saiki CB. Cancer Pain Management. *Mayo Clin Proc.* 2015;90(10):1428-1439.
- Moeschler SM, Rosenberg C, Trainor D, et al. Interventional modalities to treat cancer-related pain. *Hosp Pract (1995).* 2014;42(5):14-23.
- Özkan A. Kanserli çocuklarda ağrı. *Klinik gelişim.* 2007;20(2):182-195.
- Friedrichsdorf SJ, Nugent AP. Management of neuropathic pain in children with cancer. *Curr Opin Support Palliat Care.* 2013;7(2):131-138.
- Duffy EA, Dias N, Hendricks-Ferguson V, et al. Perspectives on Cancer Pain Assessment and Management in Children. *Semin Oncol Nurs.* 2019;35(3):261-273.
- Soliman IE, Broadman LM, Hannallah RS, et al. Comparison of the analgesic effects of EMLA (eutectic mixture of local anesthetics) to intradermal lidocaine infiltration prior to venous cannulation in unpremedicated children. *Anesthesiology.* 1988;68:804-806.
- Gimenez JCJ, Oliveras M, Hidalgo M, et al. Anesthetic efficacy of eutectic prilocaine-lidocaine cream in pediatric oncology patients undergoing lumbar puncture. *Ann Pharmacother.* 1996;30:1236-1239.
- Lioffi C, Hatira P. Clinical hypnosis versus cognitive behavioral training for pain management with pediatric cancer patients undergoing bone marrow aspirations. *Int J Clin Hypn.* 1999; 47: 104-16.
- Uzunoglu S, Çiçin İ. Kanser hastalarında ağrıya yaklaşım. *Klinik gelişim.* 2011;24:14-20.
- Lewis MA, Zhao F, Jones D, et al. Neuropathic symptoms and their risk factors in medical oncology outpatients with colorectal vs. breast, lung, or prostate cancer: results from a prospective multicenter study. *J Pain Symptom Manage.* 2015;49(6):1016-1024.
- Pachman DR, Watson JC, Loprinzi CL. Therapeutic strategies for cancer treatment related peripheral neuropathies. *Curr Treat Options Oncol.* 2014;15(4):567-580.
- Bruera E, Palmer JL, Bosnjak S, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. *J Clin Oncol.* 2004;22(1):185-192.
- Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol.* 2010;28(35):5132-5139.
- Knopp-Sihota JA, Newburn-Cook CV, Homik J, et al. Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis. *Osteoporos Int.* 2012;23(1):17-38.
- Paulsen O, Klepstad P, Rosland JH, et al. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. *J Clin Oncol.* 2014;32(29):3221-3228.
- Arslan D, Tatlı AM, Üyetürk Ü. Kansere Bağlı Ağrı ve Tedavisi. *Abant Med J.* 2013;2(3):256-260.

- Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. *J Clin Oncol.* 2013;31(25):3076-3082.
- Israel FJ, Parker G, Charles M, Reymond L. Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, double-blind, placebo-controlled, crossover trial. *J Pain Symptom Manage.* 2010;39(3):548-554.
- Eti Z. Kanserde ağrı tedavisi. *Üroonkoloji bülteni.* 2005;2:16-20.
- Stockler M, Vardy J, Pillai A, Warr D. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. *J Clin Oncol.* 2004;22(16):3389-3394.
- Smith TJ, Coyne PJ, Staats PS, et al. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). *Ann Oncol.* 2005;16(5):825-833.